WallStSmart

Airbnb Inc (ABNB)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 411% more annual revenue ($62.58B vs $12.24B). ABNB leads profitability with a 20.5% profit margin vs 12.4%. ABNB appears more attractively valued with a PEG of 1.24. ABNB earns a higher WallStSmart Score of 58/100 (C).

ABNB

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 7.5Value: 7.3Quality: 4.8
Piotroski: 4/9Altman Z: 1.49

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABNBSignificantly Overvalued (-381.1%)

Margin of Safety

-381.1%

Fair Value

$27.40

Current Price

$131.81

$104.41 premium

UndervaluedFair: $27.40Overvalued
PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABNB3 strengths · Avg: 9.3/10
Return on EquityProfitability
30.2%10/10

Every $100 of equity generates 30 in profit

Market CapQuality
$77.94B9/10

Large-cap with strong market position

Profit MarginProfitability
20.5%9/10

Keeps 21 of every $100 in revenue as profit

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

ABNB4 concerns · Avg: 3.0/10
P/E RatioValuation
32.3x4/10

Premium valuation, high expectations priced in

Price/BookValuation
9.7x4/10

Trading at 9.7x book value

EPS GrowthGrowth
-23.7%2/10

Earnings declined 23.7%

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABNB

The strongest argument for ABNB centers on Return on Equity, Market Cap, Profit Margin. Profitability is solid with margins at 20.5% and operating margin at 9.7%. Revenue growth of 12.0% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : ABNB

The primary concerns for ABNB are P/E Ratio, Price/Book, EPS Growth.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

ABNB profiles as a mature stock while PFE is a declining play — different risk/reward profiles.

ABNB carries more volatility with a beta of 1.16 — expect wider price swings.

ABNB is growing revenue faster at 12.0% — sustainability is the question.

PFE generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

ABNB scores higher overall (58/100 vs 49/100), backed by strong 20.5% margins and 12.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Airbnb Inc

CONSUMER CYCLICAL · TRAVEL SERVICES · USA

Airbnb, Inc. is an American company that operates an online marketplace for lodging, primarily homestays for vacation rentals, and tourism activities, based in San Francisco, California.

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?